Last reviewed · How we verify

Eisai Co., Ltd. — Portfolio Competitive Intelligence Brief

Eisai Co., Ltd. (ESALY) pipeline: 14 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ESALY (OTC) 14 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Leqembi LECANEMAB marketed Amyloid Beta-directed Antibody [EPC] Amyloid beta A4 protein Immunology 2023-01-01
Dayvigo LEMBOREXANT marketed Orexin Receptor Antagonist [EPC] Orexin receptor type 2 Neuroscience 2019-01-01
Lenvima LENVATINIB marketed Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret Oncology 2015-01-01
Belviq LORCASERIN marketed Serotonin-2c Receptor Agonist 5-hydroxytryptamine receptor 2C Metabolic 2012-01-01
Halaven ERIBULIN marketed Microtubule Inhibitor Tubulin beta Oncology 2010-01-01
Banzel RUFINAMIDE marketed rufinamide Carbonic anhydrase 5A, mitochondrial Neuroscience 2008-01-01
Ontak DENILEUKIN DIFTITOX marketed CD25-directed Cytotoxin [EPC] Interleukin-2 receptor Oncology 1999-01-01
Ontak E7777 marketed CD25-directed Cytotoxin Interleukin-2 receptor Oncology 1999-01-01
Aricept DONEPEZIL marketed Cholinesterase Inhibitor Sigma non-opioid intracellular receptor 1 Neuroscience 1996-01-01
Hexalen ALTRETAMINE marketed Alkylating Drug Cytochrome P450 1A2 Oncology 1990-01-01
MENATETRANONE MENATETRANONE marketed Other
LEQEMBI LECANEMAB-IRMB marketed Amyloid Beta-directed Antibody [EPC] Amyloid beta A4 protein Neuroscience

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 3 shared drug classes
  2. Sanofi · 2 shared drug classes
  3. Johnson & Johnson · 2 shared drug classes
  4. Pfizer · 2 shared drug classes
  5. AstraZeneca · 1 shared drug class
  6. Avet Lifesciences · 1 shared drug class
  7. AbbVie · 1 shared drug class
  8. Apotex · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eisai Co., Ltd.:

Cite this brief

Drug Landscape (2026). Eisai Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eisai. Accessed 2026-05-13.

Related